Regulatory Focus™ > News Articles > Germany: IQWiG Recommends Combination Rilpivirine for HIV

Germany: IQWiG Recommends Combination Rilpivirine for HIV

Posted 06 July 2012 | By Louise Zornoza

In a statement on 5 June 2012, the German health technology assessment body Institute for Quality and Efficiency in Health Care (IQWiG) said it would reverse its April 2012 decision not to recommend Eviplera (rilpivirine) for HIV in fixed combination. 

The agency said in a statement its change in determination was due to the manufacturer having submitted additional information supporting this dosage form. The company used an alternative so-called viral load approach in order to demonstrate the added therapeutic value, which IQWiG recognized as valid. The viral load decrease was significant in men bit less so in women.


Read more:

IQWiG - Rilpivirine with HIV: evidence for additional benefits combined preparation

More Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe